Global Human Immunodeficiency Virus (HIV) Market

Global Human Immunodeficiency Virus (HIV) Market (2012 2017)

Report Code: UC 1697 Jan, 2019, by marketsandmarkets.com

Introduction

Human immunodeficiency virus (HIV) is a retrovirus which causes Acquired Immunodeficiency syndrome (AIDS) in humans, a condition where immune system fails, leading to opportunistic infections that is life threatening.

HIV infection occurs via transfer of blood, semen, vaginal fluid, pre-ejaculate, or breast milk and major routes of infection transmission are unsafe sex, contaminated needles, perinatal transmission, breast milk and infected blood products.

Key Take-Aways

Define and measure HIV therapeutic market by stages of development, market structure, strategically analyze each submarket, analyze HIV pipeline & marketed products and profile key players in the segment.

Research Methodology

Market information and pipeline analysis was obtained through secondary research on company websites, news articles and other standard paid and un-paid sources; Market size of the segments was calculated using the bottom-up approach.

Stakeholders

  • HIV therapeutic manufacturers
  • Contract research organizations (CROs)
  • Healthcare & research institutions

Table of Contents

1. Introduction
   1.1 Key Take-aways
   1.2 Report Description
   1.3 Markets Covered
   1.4 Research Methodology
   1.5 Stakeholders

2. Summary

3. Disease Overview
   3.1 Epidemiology

4. Current Scenario
   4.1 Market by Products
       4.1.1 Key Brands
             4.1.1.1 Truvada
                     4.1.1.1.1 Brand Name
                     4.1.1.1.2 Active Ingredient
                     4.1.1.1.3 Mechanism of action
                     4.1.1.1.4 Dosage form (s)
                     4.1.1.1.5 Latest Sales Figures
                     4.1.1.1.6 Launch Date/Year
                     4.1.1.1.7 Patent
(All the above attributes under Truvada will be covered for
the brands mentioned below)
             4.1.1.2 Atripla
             4.1.1.3 Kaletra
             4.1.1.4 Reyataz
             4.1.1.5 Sustiva
       4.1.2 Key Molecules
             4.1.2.1 Efavirenz
                     4.1.2.1.1 Trade Name
                     4.1.2.1.2 Active Ingredient
                     4.1.2.1.3 Mechanism of action
                     4.1.2.1.4 Dosage form (s)
                     4.1.2.1.5 Latest Sales Figures
                     4.1.2.1.6 Expected Launch Date/Year
                     4.1.2.1.7 Patent
(All the above attributes under Efavirenz will be covered for the molecules mentioned below)
             4.1.2.2 Emtricitabine
             4.1.2.3 Tenofovir
             4.1.2.4 Ritonavir
             4.1.2.5 Lopinavir
             4.1.2.6 Atazanavir
   4.2 Market by Mechanism of Action (MOA)
       4.2.1 Vaccines
       4.2.2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs)
       4.2.3 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
       4.2.4 Protease Inhibitors (PIs)
       4.2.5 Viral Fusion (or Entry) Inhibitors
       4.2.6 HIV Integrase Strand Transfer Inhibitors
       4.2.7 CCR5 Receptor Antagonists
   4.3 Market by Geography
       4.1.1 USA
       4.1.2 Europe (EU5)
       4.1.3 Russia & CIS countries
       4.1.4 Brazil
       4.1.5 India
       4.1.6 China
       4.1.7 SouthAfrica
       4.1.8 Turkey
   4.4 Competitive landscape
   4.5 Company profiles
       4.5.1 GlaxoSmithKline
       4.5.2 Abbott Laboratories
       4.5.3 Gilead Sciences
       4.5.4 Bristol-Myers Squibb
       4.5.5 Pfizer

5. Pipeline Analysis
   5.1 Pipeline by Phase
       5.1.1 Lead Optimization/Discovery
       5.1.2 Preclinical
       5.1.3 Phase I
       5.1.4 Phase II
       5.1.5 Phase III
       5.1.6 Pending Approval
       5.1.7 Approved
       5.1.8 Discontinued
   5.2 Molecules by Phase & their profiles
       5.2.1 TMC278
             5.2.1.1 Investigational Name
             5.2.1.2 Active Ingredient
             5.2.1.3 Mechanism of Action
             5.2.1.4 Dosage form (s)
             5.2.1.5 Sales forecast
             5.2.1.6 Expected Launch
(All the above attributes under TMC278 be covered for the
pipeline molecules mentioned below)
       5.2.2 Elvitegravir
       5.2.3 Elvitegravir/GS-9350/Emtricitabine/Tenofovir
       5.2.4 Racivir
       5.2.5 Apricitabine
       5.2.6 Tesamorelin
       5.2.7 MPC 4326
       5.2.8 S/GSK1265744
       5.2.9 UK-453061
       5.2.10 Quad Pill (tenofovir + emtricitabine + elvitegravir + GS 9350)
   5.3 HIV therapeutics Pipeline share by Mechanism of Action (MOA)
       5.3.1 Vaccines
       5.3.2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs)
       5.3.3 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
       5.3.4 Protease Inhibitors (PIs)Hemispherx Biopharma
       5.3.5 Viral Fusion (or Entry) Inhibitors
       5.3.6 HIV Integrase Strand Transfer Inhibitors
       5.3.7 CCR5 Receptor Antagonists
       5.3.8 Multi-class Combination Products/ Dual MOA products
   5.4 Competitive Landscape
   5.5 Company Profiles
       5.5.1 GlaxoSmithKline
       5.5.2 Shionogi
       5.5.3 Janssen-Cilag International NV
       5.5.4 VaxGen
       5.5.5 Tibotec Pharmaceuticals
       5.5.6 Merck
       5.5.7 Sanofi-Aventis
       5.5.8 Schering-Plough


Request for detailed methodology, assumptions & how numbers were triangulated.

Please share your problem/objectives in greater details so that our analyst can verify if they can solve your problem(s).
  • Select all
  • News-Letters with latest Market insights
  • Information & discussion on the relevant new products and services
  • Information & discussion on Market insights and Market information
  • Information & discussion on our events and conferences
    • Select all
    • Email Phone Professional and social network (Linkedin, etc)
Report Code
UC 1697
Published ON
Jan, 2019
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Global Human Immunodeficiency Virus (HIV) Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
REQUEST A FREE WORKSHOP
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
ONLINE CHAT
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
© MarketsandMarkets Research Private Ltd. All rights reserved